A pharmaceutical company, United, has seen a significant increase in value after its inhaled treatment for idiopathic pulmonary fibrosis (IPF) performed better than expected in a key study. The treatment's success in the study has reportedly had a positive impact on the company. The outcome of the study appears to be a major development for the company and its treatment for IPF.